SKS. Kinsey

S. Kinsey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


S. Kinsey has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • C. Mitchell

    Paediatric Haematology/Oncology, John Radcliffe Hospital, Oxford, United Kingdom

    1 shared publication
  • Eve Roman

    Epidemiology and Genetics Unit, Department of Health Sciences, University of York, York, UK

    1 shared publication
  • J Simpson

    Epidemiology and Genetics Unit, Department of Health Sciences, University of York, York, United Kingdom

    1 shared publication
  • J. Birch

    CRUK Paediatric and Familial Cancer Research Group, Royal Manchester Children's Hospital, Manchester, United Kingdom

    1 shared publication
  • J. Simpson

    Yorkshire Regional Centre for Paediatric Oncology & Haematology, St James's University Hospital, Leeds, UK

    1 shared publication
  • M Greaves

    Institute of Cancer Research, Chester Beatty Laboratories, London, United Kingdom

    1 shared publication

Latest Publications

  • Open Access

    Childhood Acute Lymphoblastic Leukemia and Infections in the First Year of Life: A Report from the United Kingdom Childhood Cancer Study

    by E E Roman, J Simpson, P Ansell, S Kinsey, C. Mitchell, P. McKinney, J. Birch, M Greaves, T Eden, on behalf of the United Kingdom Childhood Cancer Study Investigators

    The United Kingdom Childhood Cancer Study was designed to examine the relation between childhood cancer and preceding exposure to infectious diseases. The authors analyzed the relation between diagnosis (1991–1996) of acute lymphoblastic leukemia (ALL) at ages 2–5 years and clinically diagnosed infections in infancy. Almost all study children (96% of both cases and controls) were taken to a general practitioner for a non-immunization-associated visit at least once before their first birthday. Children diagnosed with ALL had significantly more clinically diagnosed infectious episodes in infancy than did controls; the average number of episodes was 3.6 (95% confidence interval (CI): 3.3, 3.9) versus 3.1 (95% CI: 2.9, 3.2). This case-control difference was most apparent in the neonatal period (≤1 month); 18% of controls and 24% of ALL cases were diagnosed with at least one infection (odds ratio = 1.4, 95% CI: 1.1, 1.9; p < 0.05). Cases who had more than one neonatal infectious episode tended to be diagnosed with ALL at a comparatively young age; the mean age at ALL diagnosis was 37.7 months for cases with two or more episodes versus 45.3 months for cases with only one episode or none (p < 0.01). These findings support the hypothesis that a dysregulated immune response to infection in the first few months of life promotes transition to overt ALL later in childhood.


  • Paediatric transfusion

    by J. Simpson, S. Kinsey

    Paediatric transfusion encompasses a wide range of clinical circumstances including the consideration of maternal antibodies, the changing nature of the transfusion recipient with respect to growth and development, and the management of inherited conditions which if optimally treated in early life may have problems which are delayed or less severe in adult life. Whilst the transfusion of adults and children has much in common, a child cannot be considered as a scaled down adult; there are many important differences. Developmental changes are most marked in the neonate and, together with the fact that their antibodies are maternally derived, this population provide some of the most striking challenges. The increased use of intra uterine transfusion adds an extra dimension here. A particular paediatric concern is the long-term consequences of transfusion. It is to be hoped that paediatric transfusion recipients will live long enough that any potential problems will manifest themselves, thus the aim must be to minimize transfusion risks.